Search
for

    Learn

    5 / 801 results

    Research

    5 / 18 results

    Community Join

    5 / 1000+ results

      community Veradermics VDPHL01: why isn’t anyone talking about it?

      in Treatment  41 upvotes 1 year ago
      Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

      community VDPHL01 works really quickly .. apparently?

      in Research/Science  45 upvotes 4 days ago
      VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

      community For everyone buying 2-deoxy-d-ribose (2ddr)

      in Research/Science  13 upvotes 1 year ago
      The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

      community Since there is so much hype for cosmeRNA and HMI-115...

      in Chat  47 upvotes 3 years ago
      Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.